Results 1 to 10 of about 193,424 (209)
SSRN Electronic Journal, 2011 Antidepressants as a commodity have been remarkably little-studied by economists. This study shows in new data for 27 European countries that 8% of people (and 10% of those middle-aged) take antidepressants each year.
Blanchflower, David G. +1 more
core +5 more sources
Dopamine Receptors: Is It Possible to Become a Therapeutic Target for Depression?
Frontiers in Pharmacology, 2022 Dopamine and its receptors are currently recognized targets for the treatment of several neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, some drug use addictions, as well as depression.
Fangyi Zhao +9 more
doaj +1 more source
European Psychiatry, 2022 One reason behind the failure to understand the neurobiological background of affective disorders and develop more effective treatments is their heterogeneity warranting identification of clinically meaningful endophenotypes.
X. Gonda +7 more
doaj +1 more source
Association of genetic variants of Glutamate Metabotropic Receptor 5 gene and state-anhedonia
European Psychiatry, 2022 Introduction Andedonia is one of the core symptoms of depression. It is known that in case of depressed individuals experiencing anhedonia, the classical antidepressants are often ineffective, thus investigation of this symptom would be essential ...
D. Török +6 more
doaj +1 more source
Translational Psychiatry, 2021 Although recently a large-sample GWASs identified significant loci in the background of depression, the heterogeneity of the depressive phenotype and the lack of accurate phenotyping hinders applicability of findings.
Xenia Gonda +11 more
doaj +1 more source
Epigenetic Mechanism of Early Life Stress-Induced Depression: Focus on the Neurotransmitter Systems
Frontiers in Cell and Developmental Biology, 2022 Depression has an alarmingly high prevalence worldwide. A growing body of evidence indicates that environmental factors significantly affect the neural development and function of the central nervous system and then induce psychiatric disorders.
Ziqian Cheng +7 more
doaj +1 more source
Pharmacogenetics of Antidepressants [PDF]
Frontiers in Pharmacology, 2011 Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD response. During the recent years the possible influence of a set of candidate genes as genetic predictors of AD response efficacy was investigated by us and others.
Crisafulli C +6 more
openaire +6 more sources
Improvement of hedonic perception of odors as a marker of treatment response to escitalopram: olfactory changes through an open-label antidepressant trial [PDF]
Brazilian Journal of Psychiatry, 2023 Objectives: To assess olfactory functions (threshold, identification, and hedonic valence) of depressed subjects before and after an 8-week trial of escitalopram and compare the results of responders and nonresponders.
François Kazour +7 more
doaj +1 more source
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. [PDF]
, 2020 Predicting antidepressant response has been a clinical challenge for mood disorder. Although several genome-wide association studies have suggested a number of genetic variants to be associated with antidepressant response, the sample sizes are small and
Aitchison, Katherine J +14 more
core +2 more sources
Frontiers in Aging Neuroscience, 2023 BackgroundVortioxetine has demonstrated procognitive effects in patients with major depressive disorder (MDD). We assessed the effectiveness and safety of vortioxetine in a cohort of patients with MDD and comorbid Alzheimer’s disease participating in a ...
Eduardo Cumbo +3 more
doaj +1 more source